fasinumab   Click here for help

GtoPdb Ligand ID: 8965

Synonyms: REGN475 | SAR164877
Compound class: Antibody
Comment: Fasinumab is an investigational, fully human IgG4κ monoclonal antibody targeting nerve growth factor (NGF).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record.
BLAST peptide sequence analysis reveals identical matches to peptide sequences submitted with patent US7988967 [4], with the preferred antibody being called REGN475 therein. REGN475 exhibits high specificity for human NGF, does not cross-react with closely related neurotrophin-3 (NT-3) and inhibits binding of NGF to its receptors TrkA (NTRK1) and p75 (NGFR) [4].
No information available.
Summary of Clinical Use Click here for help
Fasinumab is being evaluated as a monotherapy in Phase 3 clinical trial (NCT02620020) for its potential to treat chronic low back pain.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
An extensive body of evidence indicates a pivotal contribution of NGF to pain mechanisms in the adult mammalian nervous system, with elevated levels of NGF reported in several painful conditions in humans [1-2]. Fasinumab specifically neutralizes the biological actions of human NGF, and this is expected to produce clinical pain relief [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02620020 A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain Phase 2/Phase 3 Interventional Regeneron Pharmaceuticals